Product Reports Resources Pricing Login Book a demo

Maxcyte

Biotech & Life Sciences · Gaithersburg, United States · Founded 1999 · IPO 2016

MaxCyte operates in the biotechnology sector, specializing in scalable transfection systems that enhance cell engineering processes. The company serves a diverse range of clients including pharmaceutical companies, biotechnology firms, and academic institutions. MaxCyte's primary market is the life sciences industry, focusing on areas such as cell therapy, gene editing, and protein production. The business model revolves around selling its proprietary transfection systems and related services, which are designed to improve the efficiency, potency, and efficacy of cell-based therapies. Revenue is generated through the sale of these systems, as well as through long-term service agreements and licensing deals. MaxCyte's technology is particularly valuable for its ability to seamlessly scale from early research stages to commercial manufacturing, making it a critical tool for advancing therapeutic development. Keywords: biotechnology, transfection systems, cell engineering, gene editing, cell therapy, protein production, life sciences, scalable technology, pharmaceutical, academic institutions.

Valuation $23M
Revenue $31M
Total funding $50–100M
Power Law Colt$25–100M revenue

Investors

7 investors on Maxcyte's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 3 investors entered at this stage
Intersouth Partners
Tall Oaks Capital Partners
Harbert Growth Partners
Series B+ 4 investors entered at this stage
Harbert Growth Partners
Sofinnova Partners
Intersouth Partners
Tall Oaks Capital Partners

Global footprint

Where Maxcyte has talent and traffic

Workforce by country
8 countries with
team presence
🇺🇸 United States81.6%
🇬🇧 United Kingdom4.6%
🇫🇷 France3.5%
🇳🇱 Netherlands3.5%
🇨🇳 China2.3%
Top 5 of 8 shown
Web traffic by country
11K monthly visits
across markets
🇺🇸 United States50%
🇯🇵 Japan15.5%
🇮🇳 India9.1%
🇸🇪 Sweden7.3%
🇨🇦 Canada7.3%
Top 5 markets shown

Talent graph

The shape of Maxcyte's talent

Dealroom maps Maxcyte's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

5 standout operatorsDealroom-flagged across the org
1 AI specialistincl. 1 core researchers
105 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Maxcyte's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about Maxcyte

An AI-synthesized read of the highest-engagement posts about Maxcyte on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Maxcyte on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles